Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer

Open access
Brown, Jason R, Chan, Daniel K., Shank, Jessica J, Griffith, Kent A., Fan, Huihui, Szulawski, Robert, Yang, Kun, Reynolds, R. Kevin, Johnston, Carolyn, McLean, Karen, Uppal, Shitanshu, Liu, J. Rebecca, Cabrera, Lourdes, Taylor, Sarah E, Orr, Brian C., Modugno, Francesmary, Mehta, Pooja, Bregenzer, Michael, Mehta, Geeta, Shen, Hui, Coffman, Lan, Buckanovich, Ronald J. · 2020 · JCI Insight

Abstract

BACKGROUNDEpidemiologic studies suggest that metformin has antitumor effects. Laboratory studies indicate metformin impacts cancer stem-like cells (CSCs). As part of a phase II trial, we evaluated the impact of metformin on CSC number and on carcinoma-associated mesenchymal stem cells (CA-MSCs) and clinical outcomes in nondiabetic patients with advanced-stage epithelial ovarian cancer (EOC).METHODSThirty-eight patients with stage IIC (n = 1)/III (n = 25)/IV (n = 12) EOC were treated with either (a) neoadjuvant metformin, debulking surgery, and adjuvant chemotherapy plus metformin or (b) neoadjuvant chemotherapy and metformin, interval debulking surgery, and adjuvant chemotherapy plus metformin. Metformin-treated tumors, compared with historical controls, were evaluated for CSC number and chemotherapy response. Primary endpoints were (a) a 2-fold or greater reduction in aldehyde dehydrogenase-positive (ALDH+) CD133+ CSCs and (b) a relapse-free survival at 18 months of more than 50%.RESULTSMetformin was well tolerated. Median progression-free survival was 18.0 months (95% CI 14.0-21.6) with relapse-free survival at 18 months of 59.3% (95% CI 38.6-70.5). Median overall survival was 57.9 months (95% CI 28.0-not estimable). Tumors treated with metformin had a 2.4-fold decrease in ALDH+CD133+ CSCs and increased sensitivity to cisplatin ex vivo. Furthermore, metformin altered the methylation signature in CA-MSCs, which prevented CA-MSC-driven chemoresistance in vitro.CONCLUSIONTranslational studies confirm an impact of metformin on EOC CSCs and suggest epigenetic change in the tumor stroma may drive the platinum sensitivity ex vivo. Consistent with this, metformin therapy was associated with better-than-expected overall survival, supporting the use of metformin in phase III studies.TRIAL REGISTRATIONClinicalTrials.gov NCT01579812.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.133247

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 198

Metadata

Authors
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., Uppal, S., Liu, J. R., Cabrera, L., Taylor, S. E., Orr, B. C., Modugno, F., Mehta, P., Bregenzer, M., Mehta, G., Shen, H., Coffman, L., & Buckanovich, R. J.
Venue
JCI Insight
Published
2020-05-05
Volume
5
Issue
11
ISSN
2379-3708 (ISSN-L)
OpenAlex
W3022053420
Cited by
198
References
4
FWCI
8.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. https://app.cochat.ai/papers/10.1172/jci.insight.133247
The paper
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., Uppal, S., Liu, J. R., Cabrera, L., Taylor, S. E., Orr, B. C., Modugno, F., Mehta, P., Bregenzer, M., Mehta, G., . . . Buckanovich, R. J. (2020). Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. https://doi.org/10.1172/jci.insight.133247

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.